vs
LG化学（CHE）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是LG化学的3.4倍（$1.4B vs $420.0M）。LG化学净利率更高（15.8% vs 3.6%，领先12.2%）。通用电气医疗同比增速更快（12.2% vs 3.1%）。过去两年通用电气医疗的营收复合增速更高（13.0% vs 5.9%）
LG化学是韩国最大的化工企业，总部位于韩国首尔，2021年按销售额统计为全球第九大化工企业。其前身为生产化妆品的乐喜化学工业株式会社，目前已全面转型为仅面向企业客户的B2B经营模式。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
CHE vs OPCH — 直观对比
营收规模更大
OPCH
是对方的3.4倍
$420.0M
营收增速更快
OPCH
高出9.1%
3.1%
净利率更高
CHE
高出12.2%
3.6%
两年增速更快
OPCH
近两年复合增速
5.9%
损益表 — Q1 2026 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $420.0M | $1.4B |
| 净利润 | $66.3M | $51.8M |
| 毛利率 | — | 19.0% |
| 营业利润率 | 20.1% | 5.9% |
| 净利率 | 15.8% | 3.6% |
| 营收同比 | 3.1% | 12.2% |
| 净利润同比 | -7.6% | -3.8% |
| 每股收益（稀释后） | — | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHEOPCH
| Q1 26 | $420.0M | — | ||
| Q4 25 | $639.3M | — | ||
| Q3 25 | $624.9M | $1.4B | ||
| Q2 25 | $618.8M | $1.4B | ||
| Q1 25 | $646.9M | $1.3B | ||
| Q4 24 | $411.0M | $1.3B | ||
| Q3 24 | $391.4M | $1.3B | ||
| Q2 24 | $374.6M | $1.2B |
净利润CHEOPCH
| Q1 26 | $66.3M | — | ||
| Q4 25 | $76.8M | — | ||
| Q3 25 | $64.2M | $51.8M | ||
| Q2 25 | $52.5M | $50.5M | ||
| Q1 25 | $71.8M | $46.7M | ||
| Q4 24 | $90.3M | $60.1M | ||
| Q3 24 | $75.8M | $53.9M | ||
| Q2 24 | $70.9M | $53.0M |
毛利率CHEOPCH
| Q1 26 | — | — | ||
| Q4 25 | 35.2% | — | ||
| Q3 25 | 31.5% | 19.0% | ||
| Q2 25 | 29.8% | 19.0% | ||
| Q1 25 | 33.5% | 19.7% | ||
| Q4 24 | 1.2% | 21.3% | ||
| Q3 24 | -1.2% | 20.1% | ||
| Q2 24 | -4.1% | 20.3% |
营业利润率CHEOPCH
| Q1 26 | 20.1% | — | ||
| Q4 25 | 15.7% | — | ||
| Q3 25 | 12.0% | 5.9% | ||
| Q2 25 | 11.0% | 5.8% | ||
| Q1 25 | 14.6% | 5.9% | ||
| Q4 24 | 27.7% | 6.9% | ||
| Q3 24 | 23.5% | 6.7% | ||
| Q2 24 | 23.5% | 6.6% |
净利率CHEOPCH
| Q1 26 | 15.8% | — | ||
| Q4 25 | 12.0% | — | ||
| Q3 25 | 10.3% | 3.6% | ||
| Q2 25 | 8.5% | 3.6% | ||
| Q1 25 | 11.1% | 3.5% | ||
| Q4 24 | 22.0% | 4.8% | ||
| Q3 24 | 19.4% | 4.2% | ||
| Q2 24 | 18.9% | 4.3% |
每股收益（稀释后）CHEOPCH
| Q1 26 | — | — | ||
| Q4 25 | $5.45 | — | ||
| Q3 25 | $4.46 | $0.32 | ||
| Q2 25 | $3.57 | $0.31 | ||
| Q1 25 | $4.86 | $0.28 | ||
| Q4 24 | $6.00 | $0.36 | ||
| Q3 24 | $5.00 | $0.31 | ||
| Q2 24 | $4.65 | $0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.9M | $309.8M |
| 总债务越低越好 | $91.2M | $1.2B |
| 股东权益账面价值 | $848.0M | $1.4B |
| 总资产 | $1.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.11× | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资CHEOPCH
| Q1 26 | $16.9M | — | ||
| Q4 25 | $74.5M | — | ||
| Q3 25 | $129.8M | $309.8M | ||
| Q2 25 | $249.9M | $198.8M | ||
| Q1 25 | $173.9M | $171.4M | ||
| Q4 24 | $178.3M | $412.6M | ||
| Q3 24 | $238.5M | $483.0M | ||
| Q2 24 | $222.9M | $376.9M |
总债务CHEOPCH
| Q1 26 | $91.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B |
股东权益CHEOPCH
| Q1 26 | $848.0M | — | ||
| Q4 25 | $979.4M | — | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.2B | $1.4B | ||
| Q2 24 | $1.2B | $1.4B |
总资产CHEOPCH
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.6B | $3.5B | ||
| Q2 25 | $1.7B | $3.4B | ||
| Q1 25 | $1.7B | $3.3B | ||
| Q4 24 | $1.7B | $3.4B | ||
| Q3 24 | $1.8B | $3.4B | ||
| Q2 24 | $1.7B | $3.3B |
负债/权益比CHEOPCH
| Q1 26 | 0.11× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.82× | ||
| Q4 24 | — | 0.79× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $88.2M | $139.4M |
| 自由现金流经营现金流 - 资本支出 | — | $130.2M |
| 自由现金流率自由现金流/营收 | — | 9.1% |
| 资本支出强度资本支出/营收 | 4.1% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.33× | 2.69× |
| 过去12个月自由现金流最近4个季度 | — | $220.7M |
8季度趋势，按日历期对齐
经营现金流CHEOPCH
| Q1 26 | $88.2M | — | ||
| Q4 25 | $133.5M | — | ||
| Q3 25 | $83.4M | $139.4M | ||
| Q2 25 | $138.6M | $90.3M | ||
| Q1 25 | $32.7M | $-7.2M | ||
| Q4 24 | $164.9M | $36.1M | ||
| Q3 24 | $90.5M | $160.4M | ||
| Q2 24 | $77.5M | $195.7M |
自由现金流CHEOPCH
| Q1 26 | — | — | ||
| Q4 25 | $117.2M | — | ||
| Q3 25 | $66.0M | $130.2M | ||
| Q2 25 | $122.8M | $81.2M | ||
| Q1 25 | $19.5M | $-16.6M | ||
| Q4 24 | $152.2M | $25.8M | ||
| Q3 24 | $77.0M | $150.7M | ||
| Q2 24 | $66.5M | $185.9M |
自由现金流率CHEOPCH
| Q1 26 | — | — | ||
| Q4 25 | 18.3% | — | ||
| Q3 25 | 10.6% | 9.1% | ||
| Q2 25 | 19.8% | 5.7% | ||
| Q1 25 | 3.0% | -1.2% | ||
| Q4 24 | 37.0% | 2.0% | ||
| Q3 24 | 19.7% | 11.8% | ||
| Q2 24 | 17.7% | 15.1% |
资本支出强度CHEOPCH
| Q1 26 | 4.1% | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 2.6% | 0.6% | ||
| Q1 25 | 2.1% | 0.7% | ||
| Q4 24 | 3.1% | 0.8% | ||
| Q3 24 | 3.5% | 0.8% | ||
| Q2 24 | 3.0% | 0.8% |
现金转化率CHEOPCH
| Q1 26 | 1.33× | — | ||
| Q4 25 | 1.74× | — | ||
| Q3 25 | 1.30× | 2.69× | ||
| Q2 25 | 2.64× | 1.79× | ||
| Q1 25 | 0.46× | -0.15× | ||
| Q4 24 | 1.83× | 0.60× | ||
| Q3 24 | 1.19× | 2.98× | ||
| Q2 24 | 1.09× | 3.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHE
| Homecare | $371.1M | 88% |
| Inpatient | $35.9M | 9% |
| Other | $13.0M | 3% |
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
